AGIOS PHARMACEUTICALS, INC. financial data

Symbol
AGIO on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 30 Oct 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1431% % 35%
Quick Ratio 43% % 41%
Debt-to-equity 7% % -45%
Return On Equity -28% % -140%
Return On Assets -26% % -143%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58,313,812 shares 2.3%
Common Stock, Shares, Outstanding 58,279,876 shares 2.2%
Entity Public Float $2,416,161,200 USD 55%
Weighted Average Number of Shares Outstanding, Basic 58,139,277 shares 2.1%
Weighted Average Number of Shares Outstanding, Diluted 58,139,277 shares -0.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $44,791,000 USD 36%
Research and Development Expense $334,289,000 USD 13%
Costs and Expenses $520,382,000 USD 18%
Operating Income (Loss) $475,591,000 USD -17%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $103,433,000 USD -110%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $401,265,000 USD -160%
Earnings Per Share, Basic -6 USD/shares -159%
Earnings Per Share, Diluted -6 USD/shares -159%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $92,710,000 USD -63%
Cash, Cash Equivalents, and Short-term Investments $1,300,000,000 USD -24%
Inventory, Net $32,034,000 USD 21%
Assets, Current $1,033,109,000 USD -3.8%
Property, Plant and Equipment, Net $10,675,000 USD -9.7%
Operating Lease, Right-of-Use Asset $33,650,000 USD -27%
Other Assets, Noncurrent $3,930,000 USD -3.1%
Assets $1,385,705,000 USD -23%
Accounts Payable, Current $19,553,000 USD 14%
Employee-related Liabilities, Current $19,593,000 USD 11%
Accrued Liabilities, Current $37,217,000 USD 12%
Liabilities, Current $74,757,000 USD -37%
Operating Lease, Liability, Noncurrent $26,528,000 USD -40%
Other Liabilities, Noncurrent $90,000 USD -92%
Liabilities $101,375,000 USD -39%
Retained Earnings (Accumulated Deficit) $453,666,000 USD -766%
Stockholders' Equity Attributable to Parent $1,284,330,000 USD -21%
Liabilities and Equity $1,385,705,000 USD -23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $111,489,000 USD -12%
Net Cash Provided by (Used in) Financing Activities $1,619,000 USD -72%
Net Cash Provided by (Used in) Investing Activities $112,587,000 USD -9.6%
Common Stock, Shares Authorized 125,000,000 shares 0%
Common Stock, Shares, Issued 74,496,287 shares 1.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,717,000 USD -91%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $92,710,000 USD -63%
Deferred Tax Assets, Valuation Allowance $275,571,000 USD -27%
Deferred Tax Assets, Gross $287,477,000 USD -27%
Operating Lease, Liability $44,515,000 USD -27%
Payments to Acquire Property, Plant, and Equipment $766,000 USD 443%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $402,634,000 USD -159%
Lessee, Operating Lease, Liability, to be Paid $47,664,000 USD -29%
Property, Plant and Equipment, Gross $68,172,000 USD 0.83%
Operating Lease, Liability, Current $17,987,000 USD 10%
Lessee, Operating Lease, Liability, to be Paid, Year Two $20,755,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $20,151,000 USD 3.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,149,000 USD -49%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,479,000 USD -83%
Deferred Tax Assets, Operating Loss Carryforwards $26,492,000 USD -59%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25,000,000 shares 0%
Unrecognized Tax Benefits $31,591,000 USD 11%
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,479,000 USD -83%
Operating Lease, Payments $19,354,000 USD 4.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $49,331,000 USD 7.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%